Praetego is a preclinical stage pharmaceutical company committed to protecting patients from the chronic diseases of aging, starting with Alzheimer’s Disease.
Praetego’s first-in-class small molecule series, the Amadorins, possess a multi-functional mechanism that inhibits early drivers of pathology leading to neurodegeneration and serious diabetic complications. Animal and safety data supports the application of our candidates to limit Alzheimer’s Disease (AD), Diabetic Neuropathy (DPN), and Diabetic Retinopathy (DR). We are focused on Alzheimer’s Disease and in bringing our lead candidate to clinic as a fundamental alternative to current options.